Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology (symbol: CYAD) is a clinical-stage biopharmaceutical company founded in 2007. The company is renowned for its expertise in cell-based therapies, particularly in taking them from the initial research phase to Phase III clinical trials. Celyad boasts robust manufacturing and logistical infrastructure designed to support the development of complex cell-based products.
Celyad's business model is rooted in strategic partnerships with esteemed research institutions such as Dartmouth College. These collaborations are instrumental in advancing their innovative programs from bench research to commercial applications.
One of the company's major focus areas is immuno-oncology, where it is pioneering the development of natural killer receptor T-cells (NKR-T cells) aimed at treating cancer. This unique therapeutic approach has shown promise in targeting and potentially destroying a wide variety of tumor types, positioning Celyad at the forefront of cancer treatment innovation.
Listed on Euronext Brussels, Euronext Paris, and NASDAQ under the ticker symbol CYAD, Celyad continues to gain recognition for its groundbreaking work in the biotech industry. The financial condition of the company is robust, with ongoing projects that underscore its commitment to transforming cancer care. Recent achievements and current projects reflect a steadfast dedication to clinical excellence and innovation.
Celyad Oncology (Euronext: CYAD) announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, November 6-10, 2024. The first poster (Abstract 262) focuses on PSMA/NKG2DL tandem CAR T-cells to improve anti-tumor efficacy against prostate cancer, to be presented on November 9. The second poster (Abstract 1133) discusses efficient and safe modulation of multiple target genes in CAR T-cells using a miRNA-based shRNA platform, to be presented on November 8.
Both posters will be available in the poster hall and virtually to SITC Annual Meeting registrants from November 7 at 10 a.m. ET. The posters will also be archived on Celyad Oncology's website under the 'Scientific Publications' section.
Celyad Oncology (Euronext: CYAD) has appointed Matt Kane as its new Chief Executive Officer, effective October 1st, 2024. Kane brings over 20 years of experience in entrepreneurial, CEO, and board roles, with expertise in genome editing and allogeneic CAR T-cell therapies. His career highlights include:
- Raising over $500M in equity financings
- Forming partnerships valued at over $4B
- Co-founding Precision BioSciences (DTIL) in 2006
- Leading Precision's IPO and development of four allogeneic CAR T therapies
- Recent CEO role at Tune Therapeutics, an epigenetic editing company
Kane's appointment aligns with Celyad's focus on CAR T technology and ambitious plans for growth and development in the oncology space.
Celyad Oncology (CYAD) reported its H1 2024 financial results and business highlights. The company is focusing on research and development, particularly in intellectual property monetization. Key developments include:
1. Proof-of-concept for multiplex shRNA non-gene edited technology and multispecific NKG2D-based CAR T-cell platform.
2. Active participation in scientific conferences and publications in peer-reviewed journals.
3. Re-initiation of C-Cath® manufacturing and commercialization.
4. Cash runway extended until Q3 2025.
Financial highlights:
- R&D expenses: €1.5M (down from €2.1M in H1 2023)
- G&A expenses: €1.7M (down from €3.7M in H1 2023)
- Net loss: €3.0M (€0.07 per share)
- Cash position: €6.2M as of June 30, 2024
FAQ
What is the market cap of CYAD (CYAD)?
What does Celyad Oncology specialize in?
When was Celyad Oncology founded?
On which stock exchanges is Celyad listed?
What is the company's ticker symbol?
Who are Celyad's key research partners?
What are natural killer receptor T-cells (NKR-T cells)?
What is Celyad's business model?
What are some recent achievements of Celyad Oncology?
What is the status of Celyad's financial condition?
How can I stay updated on Celyad's latest news?
